Published in Bioorg Med Chem Lett on October 02, 2009
Developing β-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem (2011) 1.37
BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease. Chem Soc Rev (2014) 1.14
Creation of Novel Cores for β-Secretase (BACE-1) Inhibitors: A Multiparameter Lead Generation Strategy. ACS Med Chem Lett (2014) 0.75
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet (2008) 2.88
ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res (2003) 2.29
Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci U S A (2007) 2.05
Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2003) 2.03
Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J (2004) 1.98
Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem (2005) 1.73
The prion protein and lipid rafts. Mol Membr Biol (2006) 1.54
The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci (2002) 1.51
eHiTS: a new fast, exhaustive flexible ligand docking system. J Mol Graph Model (2006) 1.44
The activation peptide cleft exposed by thrombin cleavage of FXIII-A(2) contains a recognition site for the fibrinogen α chain. Blood (2013) 1.42
Assigning functions to distinct regions of the N-terminus of the prion protein that are involved in its copper-stimulated, clathrin-dependent endocytosis. J Cell Sci (2005) 1.38
Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis. Traffic (2010) 1.36
Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center. Antimicrob Agents Chemother (2008) 1.35
Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques. J Antimicrob Chemother (2009) 1.35
Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria. Proc Natl Acad Sci U S A (2012) 1.34
Dual mechanisms for shedding of the cellular prion protein. J Biol Chem (2004) 1.32
pH as a trigger of peptide beta-sheet self-assembly and reversible switching between nematic and isotropic phases. J Am Chem Soc (2003) 1.32
Angiotensin-converting enzyme as a GPIase: a critical reevaluation. Nat Med (2005) 1.28
Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J Biol Chem (2007) 1.27
The involvement of lipid rafts in Alzheimer's disease. Mol Membr Biol (2006) 1.26
Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol Med (2005) 1.26
Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension (2006) 1.25
The low-density lipoprotein receptor-related protein 1 (LRP1) mediates the endocytosis of the cellular prion protein. Biochem J (2007) 1.25
Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J (2009) 1.24
The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway. J Biol Chem (2010) 1.21
eHiTS: an innovative approach to the docking and scoring function problems. Curr Protein Pept Sci (2006) 1.21
Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. J Biol Chem (2009) 1.19
The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur J Biochem (2004) 1.18
Lipid Rafts: Linking Alzheimer's Amyloid-β Production, Aggregation, and Toxicity at Neuronal Membranes. Int J Alzheimers Dis (2010) 1.17
Reactive oxygen species-mediated beta-cleavage of the prion protein in the cellular response to oxidative stress. J Biol Chem (2005) 1.12
Determinants of hepatitis C virus p7 ion channel function and drug sensitivity identified in vitro. J Virol (2009) 1.10
Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem (2005) 1.10
Visualization of detergent solubilization of membranes: implications for the isolation of rafts. Biophys J (2007) 1.09
alpha-cleavage of the prion protein occurs in a late compartment of the secretory pathway and is independent of lipid rafts. Mol Cell Neurosci (2008) 1.08
Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins. Angew Chem Int Ed Engl (2010) 1.07
Prion protein facilitates uptake of zinc into neuronal cells. Nat Commun (2012) 1.07
Prion protein and Alzheimer disease. Prion (2009) 1.05
Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry (2003) 1.04
Glypican-1 mediates both prion protein lipid raft association and disease isoform formation. PLoS Pathog (2009) 1.04
Structure-based discovery of antibacterial drugs. Nat Rev Microbiol (2010) 1.04
The N-terminal region of the prion protein ectodomain contains a lipid raft targeting determinant. J Biol Chem (2003) 1.04
Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. J Alzheimers Dis (2007) 1.04
The prion protein and neuronal zinc homeostasis. Trends Biochem Sci (2003) 1.04
PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin Ther Targets (2011) 1.02
Prion protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the transmembrane LRP1. J Biol Chem (2013) 1.01
The nature of Staphylococcus aureus MurA and MurZ and approaches for detection of peptidoglycan biosynthesis inhibitors. Mol Microbiol (2009) 1.01
Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein. J Biol Chem (2011) 1.00
A broad-spectrum fluorescence-based peptide library for the rapid identification of protease substrates. Proteomics (2006) 1.00
The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg Med Chem Lett (2005) 1.00
CLiDE Pro: the latest generation of CLiDE, a tool for optical chemical structure recognition. J Chem Inf Model (2009) 0.99
Assay platform for clinically relevant metallo-β-lactamases. J Med Chem (2013) 0.99
Route Designer: a retrosynthetic analysis tool utilizing automated retrosynthetic rule generation. J Chem Inf Model (2009) 0.98
Endoperoxide carbonyl falcipain 2/3 inhibitor hybrids: toward combination chemotherapy of malaria through a single chemical entity. J Med Chem (2010) 0.98
The kinetics of phase separation in asymmetric membranes. Biophys J (2005) 0.97
Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Biochem Pharmacol (2007) 0.97
Surface coat remodeling during differentiation of Trypanosoma brucei. J Biol Chem (2003) 0.97
The role of lipid rafts in prion protein biology. Front Biosci (Landmark Ed) (2011) 0.96
ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol (2002) 0.95
Rab GTPase regulation of VEGFR2 trafficking and signaling in endothelial cells. Arterioscler Thromb Vasc Biol (2009) 0.95
Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. FEBS Lett (2007) 0.95
Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem (2007) 0.95
N-glycans, not the GPI anchor, mediate the apical targeting of a naturally glycosylated, GPI-anchored protein in polarised epithelial cells. J Cell Sci (2004) 0.94
Prion protein is reduced in aging and in sporadic but not in familial Alzheimer's disease. J Alzheimers Dis (2010) 0.94
The role of zinc in Alzheimer's disease. Int J Alzheimers Dis (2010) 0.94
Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid-beta proteins. Semin Cell Dev Biol (2007) 0.93
Antimalarial and antitumor evaluation of novel C-10 non-acetal dimers of 10beta-(2-hydroxyethyl)deoxoartemisinin. J Med Chem (2004) 0.92
Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. J Med Chem (2009) 0.92
Tethering the N-terminus of the prion protein compromises the cellular response to oxidative stress. J Neurochem (2003) 0.92
The Caenorhabditis elegans orthologue of mammalian puromycin-sensitive aminopeptidase has roles in embryogenesis and reproduction. J Biol Chem (2003) 0.90
Effect of hydrophobic mismatch on phase behavior of lipid membranes. Biophys J (2006) 0.90
ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci (2004) 0.89
Alkaline phosphatase is increased in both brain and plasma in Alzheimer's disease. Neurodegener Dis (2011) 0.89
Molecular complexity analysis of de novo designed ligands. J Med Chem (2006) 0.88
Design and synthesis of new hydroxyethylamines as inhibitors of D-alanyl-D-lactate ligase (VanA) and D-alanyl-D-alanine ligase (DdlB). Bioorg Med Chem Lett (2009) 0.87
Plasma angiotensin-converting enzyme in Alzheimer's disease. J Alzheimers Dis (2009) 0.87
Furanyl-rhodanines are unattractive drug candidates for development as inhibitors of bacterial RNA polymerase. Antimicrob Agents Chemother (2010) 0.87
Secretase-mediated cell surface shedding of the angiotensin-converting enzyme. Protein Pept Lett (2004) 0.87
Emerging and potential therapies for Alzheimer's disease. Expert Opin Ther Targets (2008) 0.87
The bradykinin-degrading aminopeptidase P is increased in women taking the oral contraceptive pill. J Renin Angiotensin Aldosterone Syst (2008) 0.86
Comparison of the reactivity of antimalarial 1,2,4,5-tetraoxanes with 1,2,4-trioxolanes in the presence of ferrous iron salts, heme, and ferrous iron salts/phosphatidylcholine. J Med Chem (2011) 0.86
Structure-based design of anti-infectives. Ann N Y Acad Sci (2010) 0.86
Plasma alkaline phosphatase is elevated in Alzheimer's disease and inversely correlates with cognitive function. Int J Mol Epidemiol Genet (2011) 0.85
Structure-activity relationship of hydroxamate-based inhibitors on the secretases that cleave the amyloid precursor protein, angiotensin converting enzyme, CD23, and pro-tumor necrosis factor-alpha. Biochemistry (2002) 0.85
The first de novo-designed antagonists of the human NK(2) receptor. J Med Chem (2005) 0.85
Glycosylation efficiency of Asn-Xaa-Thr sequons is independent of distance from the C-terminus in membrane dipeptidase. Glycobiology (2003) 0.85
Factors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenases. J Med Chem (2012) 0.84
Identification and characterisation of the angiotensin converting enzyme-3 (ACE3) gene: a novel mammalian homologue of ACE. BMC Genomics (2007) 0.84
Membrane raft actin deficiency and altered Ca2+-induced vesiculation in stomatin-deficient overhydrated hereditary stomatocytosis. Biochim Biophys Acta (2007) 0.83
Pregnenolone sulphate-independent inhibition of TRPM3 channels by progesterone. Cell Calcium (2011) 0.83
Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis. FEBS J (2005) 0.83
Protective effect of prion protein via the N-terminal region in mediating a protective effect on paraquat-induced oxidative injury in neuronal cells. J Neurosci Res (2008) 0.83
Rationale design of biotinylated antimalarial endoperoxide carbon centered radical prodrugs for applications in proteomics. J Med Chem (2010) 0.83